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ABSTRACT
The Insm1 gene encodes a zinc finger factor expressed in many
endocrine organs. We show here that Insm1 is required for
differentiation of all endocrine cells in the pituitary. Thus, in Insm1
mutant mice, hormones characteristic of the different pituitary cell
types (thyroid-stimulating hormone, follicle-stimulating hormone,
melanocyte-stimulating hormone, adrenocorticotrope hormone,
growth hormone and prolactin) are absent or produced at markedly
reduced levels. This differentiation deficit is accompanied by
upregulated expression of components of the Notch signaling
pathway, and by prolonged expression of progenitor markers, such
as Sox2. Furthermore, skeletal muscle-specific genes are ectopically
expressed in endocrine cells, indicating that Insm1 participates in the
repression of an inappropriate gene expression program. Because
Insm1 is also essential for differentiation of endocrine cells in the
pancreas, intestine and adrenal gland, it is emerging as a
transcription factor that acts in a pan-endocrine manner. The Insm1
factor contains a SNAG domain at its N-terminus, and we show here
that the SNAG domain recruits histone-modifying factors (Kdm1a,
Hdac1/2 and Rcor1-3) and other proteins implicated in transcriptional
regulation (Hmg20a/b and Gse1). Deletion of sequences encoding
the SNAG domain in mice disrupted differentiation of pituitary
endocrine cells, and resulted in an upregulated expression of
components of the Notch signaling pathway and ectopic expression
of skeletal muscle-specific genes. Our work demonstrates that Insm1
acts in the epigenetic and transcriptional network that controls
differentiation of endocrine cells in the anterior pituitary gland, and
that it requires the SNAG domain to exert this function in vivo.
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INTRODUCTION
The pituitary gland is a central neuroendocrine organ that relays
information from the central nervous system to peripheral targets by
secreting hormones and other factors. The anterior pituitary gland
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contains six different endocrine cell types that control physiological
processes, such as growth, stress response, metabolic status,
reproduction and lactation (Cushman and Camper, 2001). During
embryogenesis, transcription factors and signaling events control the
development of these hormone-secreting cell types (reviewed by
Zhu et al., 2005; Kelberman et al., 2009). The discovery of these
regulatory cascades facilitated genetic analyses of patients with
hormone deficiencies. All hormone-secreting cell types of the
pituitary gland derive from Rathke’s pouch. Rathke’s pouch is an
invagination of the oral ectoderm. Inductive interactions between
surrounding tissues and Rathke’s pouch control the expression of
transcription factors, such as Lhx3, Lhx4, Hesx1, Prop1 and Pitx1,
that specify fates of pituitary cells (reviewed by Ericson et al., 1998;
Rosenfeld et al., 2000). Differentiation of the six endocrine cell
types (thyrotropes, corticotropes, melanotropes, somatotropes,
lactotropes, gonadotropes) depends on transcription factors, such as
Pit1 (Pou1f1), Math3 (NeuroD4), Nr5a1 (Sf1), Tbx19 and NeuroD1
(Camper et al., 1990; Shinoda et al., 1995; Pulichino et al., 2003;
Lamolet et al., 2004; Zhu et al., 2006). Sox2 is expressed in
Rathke’s pouch and in endocrine progenitor cells during
development and in the adult, but is downregulated upon
differentiation and hormone expression (Fauquier et al., 2008;
Jayakody et al., 2012).
The Insm1 gene encodes a zinc finger transcription factor that is
expressed in various endocrine cell types as well as in tumors that
derive thereof (Goto et al., 1992; Breslin et al., 2002; Gierl et al.,
2006; Mellitzer et al., 2006; Wildner et al., 2008). Insm1 contains
five zinc finger domains of the C2H2 type, a motif frequently
associated with transcription factors (Razin et al., 2012). At the very
N-terminus, Insm1 contains a SNAG domain (Grimes et al., 1996),
which was first identified in Snail/Slug and Gfi1 and Gfi1b zinc
finger transcription factors and recruits Rcor1, the histone
deacetylases Hdac1 and Hdac2 and the histone demethylase Kdm1a
(Saleque et al., 2007; Lin et al., 2010). Rcor1 acts as a co-repressor
and was first identified together with the histone deacetylases Hdac1
and Hdac2 in the REST silencing complex (Andrés et al., 1999).
Together, these proteins modulate gene expression by chromatin
modification and provide key epigenetic information. Zinc finger
factors related to Insm1 exist in Drosophila (Nerfin-1) and
Caenorhabditis elegans (EGL-46), where they function in neuronal
differentiation, but the invertebrate homologs do not contain SNAG
domains (Wu et al., 2001; Kuzin et al., 2005). In accordance with a
potentially repressive function, Insm1 is known to bind Hdac1 and
Hdac3 (Liu et al., 2006), but whether the Insm1 SNAG domain is
responsible for this interaction has not been assessed.
Genetic analysis in mice demonstrated that Insm1 encodes a key
factor in development of endocrine cells of pancreas, intestine and
adrenal gland. Insm1 is required for differentiation but not for the
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specification of these endocrine cell types (Gierl et al., 2006;
Wildner et al., 2008). Insm1 is expressed also in endocrine cells of
the pituitary (our unpublished observations) and pituitary tumor cells
(Goto et al., 1992), but a potential function in the pituitary has not
been assessed. Here, we show that Insm1 expression in the pituitary
is initiated when endocrine cells differentiate, and persists during
further development and in the adult. Mutation of Insm1 leads to the
formation of an anterior pituitary gland of normal overall
morphology, but this pituitary is devoid of the entire repertoire of
differentiated endocrine cell types expressing the appropriate
hormones. In the mutant endocrine cells, skeletal muscle-specific
genes are ectopically expressed, indicating that Insm1 suppresses an
inappropriate differentiation program. We also define the role of the
SNAG domain in the differentiation of pituitary endocrine cells. We
used biochemistry to show that Insm1, via its SNAG domain,
interacts with a number of histone-modifying factors (i.e. Kdm1a,
Hdac1/2 and Rcor1-3) and with factors implicated in transcriptional
regulation (Hmg20a/b and Gse1). Furthermore, deletion of the
SNAG domain in vivo disrupts the differentiation of endocrine cells
in the pituitary. Our work demonstrates that Insm1 acts in the
epigenetic and transcriptional network that controls differentiation
of endocrine cells in the anterior pituitary gland, and requires the
SNAG domain to exert its role in differentiation and in suppression
of inappropriate gene expression programs.
RESULTS
Insm1 is expressed in differentiating endocrine cells of the
anterior pituitary gland
We analyzed expression of Insm1 during organogenesis of the
pituitary gland by immunohistological analysis. The first Insm1+
cells appear at embryonic day (E) 11.5 and locate to the most ventral
part of the pituitary anlage (Fig. 1A). This domain is known to
contain proliferating progenitors that initiate differentiation into the
early thyrotropes of the pituitary (Pope et al., 2006; Bilodeau et al.,
2009). Counterstaining with DAPI demonstrated nuclear localization
of the Insm1 protein (Fig. 1A, inset). At E13.5, Insm1 expression
has expanded (Fig. 1B), and is detected below the progenitor zone
known to contain proliferating progenitors (c.f. Bilodeau et al.,
2009). By E17.5, Insm1 is present in the entire anterior pituitary
(Fig. 1C,D). This indicates that Insm1 expression accompanies the
spreading of endocrine cell differentiation. Sox2 and Sox9 are
expressed in endocrine progenitors of the pituitary (Fauquier et al.,
2008; Jayakody et al., 2012), and we detected few cells that co-
express Insm1 and Sox2, or Insm1 and Sox9 at E17.5 (Fig. 1C,C′).
Instead, the majority of Insm1+ cells co-expressed hormones, as
assessed by immunohistology using a mix of antibodies directed
against pituitary hormones (Fig. 1D,D′). Further analysis indicated
that Insm1 was co-expressed with growth hormone (GH), prolactin
(Prl), thyroid-stimulating hormone (TSH), follicle-stimulating
hormone (FSH), adrenocorticotrope hormone (ACTH), as well as
melanocyte-stimulating hormone (MSH) (Fig. 1E-J). Thus, Insm1
is present in all differentiated endocrine cell types, and its expression
persists into adulthood (supplementary material Fig. S1A). In
accordance with this, we observed only very rarely Insm1+ cells that
expressed Ki67 at E17.5, indicating that most Insm1+ cells have
exited the cell cycle (Fig. 1K,K′). Insm1 was not co-expressed with
markers for fibroblasts (ER/TR7), folliculostellate cells (S100) or
endothelia (PCAM), and is thus restricted to the endocrine lineage
of the pituitary (Fig. 1L-N). This pattern indicates that Insm1
expression initiates in pituitary progenitors when differentiation of
endocrine cells begins. Insm1 continues to be expressed in
differentiated endocrine cells during development and in adulthood.
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Fig. 1. Expression of Insm1 in the developing mouse pituitary. 
(A-N) Insm1 expression was analyzed by immunohistochemistry in the
developing pituitary at E11.5 (A), E13.5 (B) and E17.5 (C-N). Insm1
expression starts around E11.5 in a few cells of the ventral domain of
Rathke’s pouch and subsequently expands, encompassing many cells in the
developing anterior lobe of the pituitary (A,B). At E17.5, Insm1 is present in
the entire anterior pituitary (C). At this stage, a few Insm1+ cells co-express
the progenitor markers Sox9 and Sox2 (C,C′), but the majority of Insm1+ cells
co-express hormones (D,D′). Insm1 is present in all endocrine cell types and
is co-expressed with GH, Prl, TSH, FSH, ACTH and MSH (E-J). Insm1 was
very rarely co-expressed with Ki67, indicating that Insm1+ cells are
postmitotic (K,K′). Insm1 is not expressed in fibroblast (L), folliculostellate (M)
or endothelia (N) cells. (O) The developmental progression of pituitary cell
types is summarized; expression of Sox2, Insm1 and other transcription
factors that contribute to the differentiation of the distinct cell types is








Furthermore, Insm1 is expressed in all endocrine cell types of the
pituitary (see Fig. 1O for a summary of the different endocrine cell
types and their expression of Insm1).
Insm1 is required for the differentiation of endocrine cells in
the anterior pituitary gland
Next, we used mouse genetics to define the role of Insm1 in the
development of endocrine cells, using a previously generated null
allele in which the Insm1 coding sequence is replaced by lacZ (Gierl
et al., 2006). As assessed by immunohistochemistry, GH was
produced at E17.5 in heterozygous Insm1lacZ animals, which served
as controls, but was not detectable in homozygous Insm1lacZ mice
(Fig. 2A,B; we refer subsequently to heterozygous and homozygous
Insm1lacZ mice also as control and Insm1lacZ mutants). In situ
hybridization demonstrated a strong reduction in Gh transcripts in
Insm1lacZ mutants (supplementary material Fig. S1B,C). Thus,
somatotropes require Insm1 for their differentiation. Similarly, TSH,
FSH and LH proteins were present in the pituitary of control
animals, but were not detectable in Insm1lacZ mutants (Fig. 2C-H),
and the corresponding mRNAs, as well as the mRNA encoding the
common α-subunit of the three hormones, Cga, were strongly
downregulated (supplementary material Fig. S1D-K). Thus,
thyrotropes and gonadotropes also require Insm1 for differentiation.
Lactotropes express Prl, which was markedly downregulated in
Insm1lacZ mutants compared with control animals (Fig. 2I,J). Finally,
melanotropes and corticotropes produce MSH and ACTH,
respectively, which are generated from a common precursor protein,
pro-opiomelanocortin (POMC). Antibodies that detect mature MSH
and ACTH demonstrated a strong reduction of these hormones in
pituitaries of homozygous Insm1lacZ mutants (Fig. 2K-N), whereas
Pomc mRNA was mildly downregulated (supplementary material
Fig. S1L,M). A further hallmark of endocrine cell differentiation is
the production of granin proteins, which are associated with
secretory vesicles. Chromogranin A (Chga) transcripts were present
at reduced levels in the pituitary of homozygous Insm1lacZ mutants
compared with control mice (Fig. 2O,P). We conclude that none of
the endocrine cell types of the pituitary differentiates correctly in
Insm1lacZ mutants, which is reflected by a lack or marked
downregulation of hormones and proteins associated with secretory
vesicles. The deficit in differentiation of endocrine cells was
accompanied by a marked increase in the number of cells expressing
Sox2 and Sox9 (Fig. 3A-D′). The supernumerary Sox2+ and Sox9+
cells co-expressed β-gal in Insm1lacZ mutants, and we noted that β-
gal+ nuclei in the anterior lobe of the pituitary were packed more
densely in mutant than in control mice (Fig. 3A-D′). Thus, the
disrupted differentiation of endocrine cells is accompanied by an
increase in the number of endocrine progenitor cells. We did not
detect obvious changes in the distribution or morphology of other
cells types of the pituitary (fibroblasts, folliculostellate cells,
endothelia) in Insm1lacZ mutant mice (Fig. 3B,B′,F,F′).
We next investigated whether the disrupted differentiation
affected proliferation and survival of endocrine cells in the pituitary.
Cell proliferation was assessed by BrdU incorporation, which
revealed no significant changes when control and Insm1lacZ mutants
were compared (supplementary material Fig. S2A-C). Terminal
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)
staining did not detect apoptosis in the pituitary at E13.5 or E15.5
(supplementary material Fig. S2D-G). The overall shape of pituitary
glands of control and homozygous mutant mice were similar at
E17.5 (Fig. 3G,H). Nissl-stained consecutive sections of the
pituitary were used to estimate the size of the pituitary at E17.5,
which detected a small decrease (~10%) in mutant mice (Fig. 3I-K).
Thus, the pituitary size is reduced mildly in Insm1lacZ mutants,
apparently owing to a denser packing of cells. We conclude that the
mutation of Insm1 interferes in a striking manner with endocrine
differentiation but not cell cycle exit in the pituitary.
Insm1 controls the expression of a pan-endocrine
differentiation program and is required to repress myogenic
genes in the pituitary
To assess global changes in gene expression, we performed gene
profiling of control and Insm1lacZ mutant pituitary glands using
Illumina microarrays. This confirmed the marked downregulation of
genes encoding pituitary hormones, and demonstrated that many
other genes that function in hormone production and secretion were
also downregulated, e.g. proprotein convertases and various granins,
such as secretogranin II/III (Table 1). Interestingly, comparison with
previous experiments that analyzed genes deregulated in the adrenal
gland and pancreas of Insm1lacZ mutants (Gierl et al., 2006; Wildner
et al., 2008) detected a set of genes that are deregulated in all three
endocrine organs (Table 2; supplementary material Fig. S5). Thus,
Insm1 functions in many endocrine cell types and its mutation
affects the expression of an overlapping gene set in different
endocrine organs.
Remarkably, further analysis of the microarray data showed that
a number of genes of the Notch pathway were upregulated in the
pituitary of Insm1lacZ mutant mice (Table 1). Among these were Dll1
and the Notch target genes Hey1, Hes1 and Hes5. We confirmed the
enhanced expression of Dll1 and Hey1 using in situ hybridization
and qPCR (Fig. 4A-F,K). Notch2 is expressed during pituitary
development (Raetzman et al., 2004), and in situ hybridization
demonstrated a pronounced upregulation of Notch2 expression in
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Fig. 2. Mutation of Insm1 disrupts
differentiation of endocrine cells in the
pituitary. (A-N) Immunohistochemical
analysis of pituitary hormone expression in
control (Insm1+/lacZ) and Insm1 mutant
(Insm1lacZ/lacZ) mice at E17.5. The expression
of GH (A,B), TSH (C,D), FSH (E,F), LH (G,H),
Prl (I,J), MSH (K,L) and ACTH (M,N) was
markedly downregulated in Insm1 mutant
pituitaries. It should be noted that Prl mRNA is
not detectable in the intermediate lobe; the
signal detected in this domain by antibodies is
thus caused by cross-reaction. (O,P) In
addition, the expression of chromogranin A
was downregulated as assessed by in situ









the Insm1lacZ mutant pituitary at E15.5; at E17.5, altered Notch2
expression was detected by qPCR but not by in situ or microarray
experiments.
In addition, the array analysis identified a marked upregulation of
a number of genes typically expressed in skeletal muscle, e.g.
mRNAs encoding myosin light polypeptide 1 (Myl1), alpha cardiac
muscle 1 actin (Actc1) expressed in skeletal and cardiac muscle, and
musculin (Msc), a myogenic transcription factor (Table 1).
Upregulated expression of Myl1 and Actc1 mRNAs in a
subpopulation of cells was confirmed by in situ hybridization and
qPCR (Fig. 4G-K). We conclude from these data that Insm1 is
required for repression of components of the Notch signaling
pathway and of skeletal muscle-specific genes in endocrine cells of
the pituitary.
The development of different endocrine cell types depends on a
number of transcription factors. In particular, somatotrope,
lactotrope and thyrotrope lineages depend on Pit1 for differentiation
(Camper et al., 1990), and Pit1 expression was indeed not detected
at E14.5 and was markedly downregulated at E17.5 in Insm1lacZ
mutants (Fig. 5A-D). Math3 controls differentiation of somatotropes
and lactotropes, and Nr5a1 the differentiation of gonadotropes
(Shinoda et al., 1995; Zhu et al., 2006). Math3 and Nr5a1 transcripts
were markedly downregulated in Insm1lacZ mutant mice (Fig. 5E-
H). Tbx19 and NeuroD1 mark differentiating corticotropes (Tbx19,
NeuroD1) and melanotropes (Tbx19) and control their
differentiation as well as POMC expression (Lamolet et al., 2001;
Pulichino et al., 2003; Lamolet et al., 2004); expression of Tbx19
and NeuroD1 was downregulated in mutant mice (Fig. 5I-L). In
conclusion, transcription factors that direct the differentiation of
endocrine cell types of the pituitary are not correctly expressed in
Insm1lacZ mutant mice. We also assessed the early specification of
endocrine cells by analyzing transcription factors, such as Hesx1,
Pitx1, Pitx2, Lhx3 and Prop1, which are known to be essential for
pituitary development (Sheng et al., 1996; Dattani et al., 1998; Wu
et al., 1998; Szeto et al., 1999; Suh et al., 2002). No obvious change
in the expression of the corresponding transcripts was detected at
E12.5 (supplementary material Fig. S3A-P). Prop1 expression was
compared at various stages, and was unchanged at E12.5 and mildly
upregulated at E14.5 and E15.5 (supplementary material Fig. S3I-
P). We conclude that in the absence of Insm1, endocrine progenitor
cells of the pituitary are correctly specified, but their differentiation
is disrupted.
Insm1 interacts with Kdm1a, Rcor1 and Hdac1/2 via its
SNAG domain
To discover Insm1-interacting proteins, we combined stable isotope
labeling by amino acids in cell culture (SILAC) and affinity
purification, an approach that can identify protein-protein
interactions with very high confidence (Selbach and Mann, 2006;
Paul et al., 2011). This technology relies on the quantification of
proteins that co-immunoprecipitate with Insm1. The proteome of
AtT-20 cells, which is a mouse corticotrope tumor cell line, was
labeled with amino acids carrying either heavy or light stable
isotopes (‘heavy’ and ‘light’ cells). ‘Heavy’ and ‘light’ cells 
were transduced with retroviruses encoding non-tagged Insm1
(Insm1wt) and FLAG-tagged Insm1 (Insm1FLAG), respectively.
Immunoprecipitates obtained from the ‘heavy’ and ‘light’ cells using
anti-FLAG antibodies were combined and subjected to mass
spectrometry-based quantification (see Fig. 6A for an outline of the
experiment). As expected, mass spectrometry found Insm1 among
the proteins most abundant for the ‘light’-label state when anti-
FLAG immunoprecipitates from ‘heavy’-labeled Insm1wt and
‘light’-labeled Insm1FLAG cells were compared. In addition, Kdm1a,
Rcor1-3, Hdac1/2, Gse1 and Hmg20a/b were identified and
quantified with similar protein ratios (Table 3). Swapping isotope
labels resulted in reciprocal abundance ratios for Insm1 and detected
co-precipitated proteins, supporting specificity of the interaction.
Western blot analysis was used to confirm these interactions, using
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Fig. 3. Mutation of Insm1 increases the
number of endocrine progenitor cells without
altering the overall morphology of the
pituitary gland. (A-F′) Immunohistochemical
analysis of endocrine progenitor cells in the
pituitary of control (Insm1+/lacZ) and mutant
(Insm1lacZ/lacZ) mice at E17.5. Increased numbers
of double-positive cells for β-gal and Sox2 (A-B′)
or Sox9 (C-D′) were observed in Insm1lacZ/lacZ
embryos compared with control littermates. No
apparent alteration of endothelial (A-B′), fibroblast
or folliculostellate (E-F′) cells was found in Insm1
mutant mice. (G,H) Whole-mount X-gal staining
revealed no obvious changes in the overall shape
of pituitary gland of homozygous mutant mice
compared with control littermates. (I-K) Estimation
of the pituitary gland volume and area detected in
consecutive sections stained with Nissl from
Insm1+/lacZ and Insm1lacZ/lacZ mice at E17.5.
*P<0.05. Scale bars: 100 μm (A-F,I,J); 20 μm (A′-








protein extracts from AtT-20 cells and from a second pituitary cell
line, the rat somatotrope line GH3. In these experiments, Kdm1a,
Rcor1 and Hdac1/2 were co-precipitated with endogenous Insm1
(Fig. 6B).
We next tested biochemically whether the SNAG domain of
Insm1 is essential for the interaction with Kdm1a, Rcor1 and
Hdac1/2. For this, cDNAs encoding FLAG-tagged Insm1 with intact
SNAG domain (Insm1FLAG) and a truncated FLAG-tagged variant
that lacks seven highly conserved amino acids at the N-terminus
were constructed (Insm1ΔSNAGFLAG); the deletion of these seven
amino acids disrupts the SNAG domain of Insm1 (Fig. 6C).
Insm1FLAG and Insm1ΔSNAGFLAG cDNAs were expressed in AtT-
20 cells and immunoprecipitated with anti-FLAG and anti-Insm1
antibodies (Fig. 6D). Kdm1a, Rcor1 and Hdac1/2 were no longer
co-immunoprecipitated with Insm1ΔSNAGFLAG, but were present in
Insm1FLAG precipitates (Fig. 6D). Similarly, Kdm1a, Rcor1 and
Hdac1/2 antibodies co-immunoprecipitated full-length Insm1FLAG,
but not Insm1ΔSNAGFLAG (Fig. 6E). Thus, Kdm1a, Rcor1 and
Hdac1/2 are recruited to Insm1 via its N-terminal SNAG domain.
The SNAG domain of Insm1 is essential for Insm1 functions
in vivo
To assess the function of the Insm1 SNAG domain in the developing
pituitary, we generated a mouse strain in which wild-type Insm1 was
replaced by a sequence encoding Insm1ΔSNAG by the use of
homologous recombination in embryonic stem cells and blastocyst
injections (supplementary material Fig. S4). We compared Insm1
protein in pituitary extracts from mice with the genotypes
Insm1ΔSNAG/+ (also called control) and Insm1ΔSNAG/lacZ (also called
Insm1ΔSNAG mutants), using anti-Insm1 and anti-FLAG antibodies.
This demonstrated that the Insm1ΔSNAG protein was present and
stable, and it was detected even at mildly increased amounts in the
pituitaries of Insm1ΔSNAG mutants compared with control mice
(Fig. 7A). To test whether this is caused by transcriptional
autoregulation, we quantified lacZ transcripts by qPCR and found
upregulated lacZ expression in Insm1ΔSNAG/lacZ compared with
Insm1lacZ/+ pituitaries mice (Fig. 7B). The heterozygous Insm1ΔSNAG
animals that were used as controls were viable and fertile and
displayed no overt phenotype.
We next compared pituitary differentiation in control and
Insm1ΔSNAG mutant mice. None of the endocrine cell types of the
pituitary differentiated correctly in Insm1ΔSNAG mutants. In particular,
we did not detect GH, TSH and FSH proteins in the pituitary
(Fig. 7C-H). Furthermore, LH, Prl, MSH and ACTH were absent or
present at reduced levels (Fig. 7I-P). The expression of pan-
endocrine genes, such as proprotein convertases and granins, were
compared using qPCR and were downregulated to similar extents in
the pituitary of Insm1lacZ and Insm1ΔSNAG mutants (Fig. 7U). By
contrast, muscle-specific genes, such as Myl1, Actc1 and Msc were
upregulated to a similar extent, as assessed by in situ hybridization
and/or qPCR (Fig. 7Q-T,V). qPCR analysis also demonstrated that
Dll1, Notch2 and the Notch target genes Hey1, Hes1 and Hes5 were
upregulated to a similar extent in the pituitary of Insm1ΔSNAG and
Insm1lacZ mutants (Fig. 7W). Overall, our data show that the SNAG
domain of Insm1 is essential for its function during the
differentiation of pituitary endocrine cell types.
4951
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Table 1. Comparison of gene expression in the pituitary of control and Insm1 mutant mice
Gene symbol Gene name Fold change P-value
Hormones
Gh* growth hormone −85.74 2.1E–09
Prl* prolactin −2.75 1.9E–04
Tshb* thyroid-stimulating hormone, β-subunit −17.95 4.2E–13
Lhb* luteinizing hormone, β-subunit −3.94 1.3E–03
Cga* glycoprotein hormones,α-subunit −7.30 3.6E–09
Pomc* pro-opiomelanocortin – –
Processing and secretion of hormones
Chga* chromogranin A −4.80 5.9E–09
Chgb* chromogranin B −17.58 1.8E–12
Pcsk1n* proprotein convertase subtilisin/kexin type 1 −5.14 1.6E–08
Pcsk2* proprotein convertase subtilisin/kexin type 2 −5.95 5.3E–07
Scg2 secretogranin II −5.25 9.7E–10
Scg3* secretogranin III −6.01 1.9E–09
Scgn secretagogin −2.39 6.5E–08
Notch signaling pathway
Dll1* delta-like 1 1.88 1E–06
Hey1* hairy/enhancer-of-split related with YRPW motif 1 2.2 3.7E–06
Hes1* hairy and enhancer of split 1 1.42 6.9E–04
Hes5* hairy and enhancer of split 5 1.2 3.2E–04
Muscle-specific genes
Myl1* myosin, light polypeptide 1 18.09 2.05E–06
Actc1* actin, alpha, cardiac muscle 1 8.02 8E–07
Sln sarcolipin 7.26 6.2E–07
Msc* musculin 5.43 4.6E–07
Thsd7b thrombospondin, type I, domain containing 7B 3.58 1.7E–07
Myh8 myosin, heavy polypeptide 8, skeletal muscle, perinatal 2.86 3.9E–06
Tnnt1 troponin T1, skeletal, slow 3.24 3.7E–07
Mustn1 musculoskeletal, embryonic nuclear protein 1 2.69 4.5E–08
Mylpf myosin light chain, phosphorylatable, fast skeletal muscle 2.80 9.5E–06
Systematic analysis of gene expression in Insm1+/lacZ and Insm1lacZ/lacZ mice using Illumina oligonucleotide microarrays. The average signal fold change is
shown. We selected the following genes for display: (1) genes encoding hormones and proteins that participate in hormone processing and secretion; (2)
components of the Notch signaling pathway; (3) muscle-specific genes.









The fact that mutant endocrine cells continue to express the
truncated Insm1ΔSNAG protein allowed us to use anti-Insm1
antibodies to analyze and quantify cells co-expressing (wild-type or
truncated) Insm1, Sox2 or Sox9 protein in control and Insm1ΔSNAG
mutants. First, we quantified overall numbers of Sox2+, Sox9+ and
Insm1+ cells in the anterior lobe of the pituitary (supplementary
material Fig. S6). This demonstrated a significant increase in the
number of Sox2+ and Sox9+, but not Insm1+ cells. Furthermore, the
proportion of Sox2+ or Sox9+ cells co-expressing Insm1 was
increased in Insm1ΔSNAG mutants compared with control mice
(Fig. 8A-F), providing further evidence that the mutant cells remain
in a progenitor state for a prolonged period. Interestingly, a
combination of in situ hybridization and immunohistology
demonstrated that a subpopulation of cells expressing the truncated
Insm1 protein co-express Myl1 (Fig. 8G,H). Thus, Insm1 acts cell-
autonomously when repressing the expression of muscle-specific
genes in the pituitary.
DISCUSSION
We show here that all endocrine cell types of the pituitary express
Insm1 and depend on Insm1 for differentiation. Early specification
of endocrine cells proceeded correctly, whereas transcription factors
that control differentiation of endocrine cells were not correctly
expressed in Insm1 mutants. Furthermore, the endocrine
differentiation program was disrupted in Insm1 mutants, and
hormones, proprotein convertases and granins were not expressed
or expressed at markedly reduced levels. In addition, we noted
prolonged expression of progenitor markers (Sox2/9), as well as
ectopic expression of Notch signaling components and of genes
typical for the muscle lineage in the Insm1 mutant pituitary
(summarized in Fig. 8I). Our previous work has demonstrated a
severe disruption of the differentiation of endocrine cells in
pancreas, intestine and adrenal medulla (Gierl et al., 2006; Wildner
et al., 2008). A comparison of the deregulated genes in the pancreas,
adrenal and pituitary glands detects a small set of overlapping genes
(Table 2). Insm1 is thus emerging as a pan-endocrine differentiation
factor.
The SNAG domain of Insm1
The SNAG domain consists of fewer than ten amino acids located
at the immediate N-terminus of the Insm1 protein. We use here
mouse genetics to show that this domain is essential for Insm1
function. The SNAG domain is found in other transcription factors,
such as Gfi1 and Snail1 (Snai1), two well characterized zinc finger
factors that act as transcriptional regulators (Hock and Orkin, 2006;
Moreno-Bueno et al., 2008; Möröy and Khandanpour, 2011). We
show in biochemical experiments that the SNAG domain of Insm1
recruits a battery of chromatin modifying enzymes, such as Kdm1a,
Rcor1-3 and Hdac1/2, as well as additional factors, such as Gse1
and Hmg20a/b.
Snail1 is a repressor of E-cadherin (cadherin 1) gene expression
and controls epithelial-mesenchymal transition of cells, for instance
in tumorigenesis (Cano et al., 2000). The SNAG domain of Snail1
also recruits Kdm1a, Rcor1/2 and Hdac1/2; it resembles the tail of
histone H3, and the active site of Kdm1a binds the histone H3 tail
and the SNAG domain (Lin et al., 2010). To the Snail1-Kdm1a
complex, Rcor is recruited, and the formation of the ternary complex
stabilizes Snail1 (Lin et al., 2010). By contrast, the steady state
levels of Insm1ΔSNAG are not markedly lowered, indicating that
Insm1 stability does not depend on the formation of the ternary
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Table 2. A common set of genes are deregulated in the pituitary, adrenal gland and pancreas of Insm1 mutant mice
Fold change Fold change Fold change 
Gene symbol Gene name in pituitary gland in adrenal gland in pancreas
Resp18 regulated endocrine-specific protein 18 −14.6*** −7.0** −4.2*
Chgb chromogranin B −17.8*** −6.8** −43.0**
Scg3 secretogranin III −6.0*** −2.0* −10.8**
Pcsk1n proprotein convertase subtilisin/kexin type 1 inhibitor −5.1*** −1.9* −2.4*
Scg2 secretogranin II −5.2*** −3.3* −44.0**
Chga chromogranin A −4.8*** −9.8** −26.2**
Gng4 guanine nucleotide binding protein (G protein) −3.3** −1.7* −2.9*
Sez6l2 seizure related 6 homolog like 2 −3.2** −2.5* −4.0**
Aplp1 amyloid beta (A4) precursor-like protein 1 −2.5** −1.8* −2.4*
Slc35d3 solute carrier family 35, member D3 −1.8** −2.8* −1.4*
Snx5 sorting nexin 5a −1.7** −1.7* −2.2*
Cplx2 complexin 2 −1.7* −1.8* −1.8*
Efcab1 EF hand calcium binding domain 1 −1.5* −1.5* −2.0*
Tnfrsf12a tumor necrosis factor receptor superfamily, member 12a −1.4* −2.2* −2.0*
Trp53inp2 transformation related protein 53 inducible nuclear protein 2 −1.3* −2.1* −1.9*
Ccrn4l CCR4 carbon catabolite repression 4-like (S. cerevisiae) −1.3* −1.3* −2.0*
Pclo piccolo (presynaptic cytomatrix protein) −1.2* −1.6* −1.7*
Hbs1l Hbs1-like (S. cerevisiae) −1.2* −1.3* −2.0*
Cyp51 cytochrome P450, family 51 −1.1* −1.7* −1.7*
Btg3 B-cell translocation gene 3 −1.1* −1.3* −1.4*
Efcab14 (4732418C07Rik) EF-hand calcium binding domain 14 −1.1* −1.4* −1.4*
Gmpr2 guanosine monophosphate reductase 2 1.1* 1.7* 2.0*
Tcea3 transcription elongation factor A (SII) 1.2* 1.3* 2.1*
Ogt O-linked N-acetylglucosamine (GlcNAc) transferase 1.3* 2.2* 1.8*
Meis1 Meis homeobox 1 1.5** 1.4* 3.1*
Bcl6 B-cell leukemia/lymphoma 6 (Bcl6) 1.6** 1.2* 1.6*
Systematic analysis of gene expression in pituitary glands, adrenal glands and pancreata of Insm1+/lacZ and Insm1lacZ/lacZ mice using Illumina or Affymetrix
microarrays. The average signal fold change is shown. We selected the following genes for display: (1) genes that are deregulated in all three endocrine










Insm1-Rcor-Kdm1a complex. The transcription factor Gfi1 is
essential for hematopoietic differentiation, and a single point
mutation in the SNAG domain of Gfi1 interferes with Gfi1 function
in hematopoietic differentiation as well as in recruitment of Kdm1a,
Rcor1/2 and Hdac1/2 (Saleque et al., 2007). Thus, the function of
the SNAG domains of Insm1, Snail1 and Gfi1 are conserved, and
they act as hub to recruit chromatin-modifying factors. The
recruitment of these modifying factors is essential for the function
of these zinc finger transcription factors.
Transcriptional deregulation in the developing pituitary of
Insm1 mutant mice
Our analysis of pituitary development in Insm1lacZ mutant mice
indicates that the differentiation of the different endocrine cell types
is disrupted and that neither the hormones nor pan-endocrine-
specific genes, such as proprotein convertases or granins, are
expressed correctly. However, morphogenesis of the pituitary
remains intact and, for instance, endocrine progenitors leave the
proliferative zone in the Insm1 mutant pituitary. This requires an
epithelial-mesenchymal transition, which thus occurs in the absence
of Insm1. The first changes that we detect during development of
endocrine cells in the pituitary of Insm1lacZ mutants are associated
with the failure to initiate expression of transcription factors that
control the lineage-specific differentiation (e.g. Pit1, Sp1, Math3).
Insm1 might thus participate in the activation of such genes or
indirectly preclude the expression of such factors. We also observed
upregulated expression of the genes encoding Notch2, the Notch
ligand Dll1 and of target genes of the Notch signaling pathway, such
as Hey1, Hes1 and Hes5. In normal development, the Notch2 and
Notch3 receptors and Hes1 are expressed in progenitor cells, but are
excluded from differentiating endocrine cells (Raetzman et al.,
2004). A tight control of Notch signaling is required for pituitary
development, and sustained Notch activation in progenitor cells by
expression of Notch1/2 intracellular domains disrupts and
dramatically delays endocrine differentiation (Raetzman et al., 2006;
Zhu et al., 2006). Furthermore, the maintenance of progenitors and
formation of melanotropes depend on the Notch target genes Hes1
and Hes5 (Kita et al., 2007; Raetzman et al., 2007). Upregulated
expression of Notch signaling components is associated with a
prolonged expression of Sox2/9, indicating that the Insm1 mutant
endocrine cells remain in a progenitor stage. The Insm1lacZ mutation
arrests differentiation of pituitary endocrine cells in fetal
development, but the lethal phenotype of the mutation precludes
analysis during postnatal stages. Thus, it is possible that by
upregulating Notch signaling, the Insm1lacZ mutation merely delays
differentiation, as described for the Notch2 gain-of-function
mutation (Raetzman et al., 2006). Upregulation of the Notch
signaling pathway, particularly of Dll1 and Hes1, was also noted in
4953
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Fig. 4. Enhanced expression of Notch2, Dll1 and Hey1 and de-
repression of skeletal muscle genes in the pituitary of Insm1 mutants.
(A-J) Analysis of Notch2 (A,B), Dll1 (C,D), Hey1 (E,F), myosin light
polypeptide 1 (Myl1; G,H) and alpha cardiac muscle 1 actin (Actc1; I,J)
expression by in situ hybridization in control (Insm1+/lacZ) and Insm1 mutant
(Insm1lacZ/lacZ) mice at E15.5 (A,B) and E17.5 (C-J). (K) Upregulated
expression of these genes was verified by qPCR. *P<0.05; ***P<0.001. Scale
bar: 100 μm.
Fig. 5. Transcription factors that regulate
differentiation of endocrine cells are
deregulated in the pituitary of Insm1 mutant
mice. (A-J) Analysis of Pit1 (A-D), Math3 (E,F),
SF1 (Nr5a1) (G,H) and Tbx19 (I,J) expression by
in situ hybridization in control (Insm1+/lacZ) and
Insm1 mutant (Insm1lacZ/lacZ) mice.
(K,L) Immunohistological analysis of NeuroD1 in
control and Insm1 mutant mice. The
developmental stages analyzed are indicated.









our previous analysis on the development of the sympathetic
nervous system in Insm1lacZ mutant mice (Wildner et al., 2008). The
fact that we observe upregulated Dll1 and Hes1 expression in
several tissues might indicate that activation of Notch is a direct and
primary event in the deregulation of gene expression caused by the
Insm1lacZ mutation.
Deletion of sequences encoding the SNAG domain of Insm1
(Insm1ΔSNAG) and the null mutation of Insm1 (Insm1lacZ) have
indistinguishable effects on the development of endocrine cells of
the pituitary, indicating that the recruitment of proteins by the SNAG
domain is essential for Insm1 function. Remarkably, conditional
mutation of Kdm1a (also known as Lsd1) in the entire anlage of the
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Fig. 6. Insm1 recruits chromatin-modifying factors
and factors implicated in transcriptional regulation
via its SNAG domain. (A) Schematic outline of the
SILAC experiment (stable isotope labeling by non-
radioactive amino acids in cell culture combined with
mass spectrometry) used to identify proteins that
interact with Insm1. Cells were grown in the presence
of amino acids labeled with heavy or light non-
radioactive isotopes, and transduced with retroviruses
encoding non-tagged Insm1 (Insm1wt) and FLAG-
tagged Insm1 (Insm1FLAG), respectively.
Immunoprecipitates from ‘heavy’ or ‘light’ cells were
pooled and analyzed by mass spectrometry.
(B) Verification of Insm1 interaction partners in AtT-20
and GH3 cell lines that derive from mouse
corticotropes and rat somatotropes, respectively.
Proteins that interact with Insm1 were co-
immunoprecipitated and identified by western blotting.
(C) Comparison of N-terminal sequences of various
transcription factors containing a SNAG domain; the
sequence of Insm1ΔSNAG is also shown. (D) Insm1
interaction partners require the SNAG domain for
binding to Insm1, as assessed by immunoprecipitation
of FLAG-tagged Insm1 and Insm1ΔSNAG and western
blotting. (E) Immunoprecipitations of Kdm1a, Rcor1
and Hdac1 co-immunoprecipitate Insm1 but not
Insm1ΔSNAG.
Table 3. Screen for Insm1-interacting proteins using SILAC technology 
Ratio H/L normalized Quant. events 
Protein symbol Protein name Ratio H/L normalized Quant. events ‘label swap’ ‘label swap’
Insm1 insulinoma-associated 1 0.02 51 9.04 63
Kdm1a lysine (K)-specific demethylase 1A 0.34 2 n.d. n.d.
Rcor1 REST corepressor 1 0.13 16 5.47 6
Rcor2 REST corepressor 2 0.27 4 5.58 2
Rcor3 REST corepressor 3 0.30 2 n.d. n.d.
Hdac1 histone deacetylase 1 0.04 1 6.13 2
Hdac2 histone deacetylase 2 0.05 5 5.44 4
Gse1 genetic suppressor element 1 0.06 27 7.25 8
Hmg20a high mobility group 20A 0.05 6 9.37 4
Hmg20b high mobility group 20B 0.14 10 10.46 4
AtT-20 cells were transfected with Insm1 and FLAG-tagged Insm1 after labeling with ‘heavy’ and ‘light’ amino acids, respectively; proteins in
immunoprecipitates obtained by the use of anti-Flag antibodies were identified using mass spectrometry. Shown are the gene symbol and name, the ratio of
the abundance of heavy and light labeled peptides of a particular protein identified by mass spectrometry (ratio H/L normalized) and the number of
quantification events/protein (quant. events). In a second experiment, ‘heavy’ and ‘light’ amino acids label was swapped (label swap). 







pituitary results in stunningly similar deficits and, like the Insm1
mutation, blocks differentiation of all endocrine cell types of the
pituitary (Wang et al., 2007). Furthermore, the expression of Prop1
but not Pit1 is correctly initiated, and Hey1 is upregulated in Kdm1a
and Insm1 mutant pituitaries (this work) (Wang et al., 2007). Kdm1a
acts as a histone demethylase that demethylates both Lys-4
(H3K4me) and Lys-9 (H3K9me) of histone H3 and acts thus in a
context-dependent manner as co-activator or co-repressor (Lee et al.,
2005; Metzger et al., 2005). It is possible that Insm1 also takes over
such dual roles in the pituitary. In support for a function as a
repressor, we observed many genes that were upregulated, among
them Dll1 and Notch target genes. Interestingly, among the top 20
upregulated genes, nine are strongly expressed in muscle tissue in
normal development. Muscle and pituitary derive from mesoderm
and ectoderm, respectively. Activation of particular gene expression
programs that are characteristic of different germ layers at such late
developmental stages is unusual. It should be noted that this ectopic
expression in the pituitary did not reach levels comparable to those
observed in mature skeletal muscle, and the changed expression
does therefore not represent a complete fate shift. The data indicate
that Insm1 participates in the repression of inappropriate
differentiation programs. We conclude that Insm1 recruits
chromatin-modifying factors and thus directs differentiation of all
endocrine cell types of the pituitary.
MATERIALS AND METHODS
Mouse strains
Generation and genotyping of Insm1lacZ mutant mice were carried out as
described (Gierl et al., 2006). The Insm1ΔSNAG targeting vector was
generated by homologous recombination in bacteria (Lee et al., 2001); in
particular, the Insm1 coding sequence was replaced by an Insm1ΔSNAG
sequence that lacks the seven N-terminal amino acids (Fig. 6C;
supplementary material Fig. S4) and contains a C-terminal 3xFLAG-tag
(Sigma-Aldrich) sequence. The targeting vector contained a self-excision
neo cassette (Bunting et al., 1999). R1/E embryonic stem cells were
electroporated and colonies that had incorporated the targeting vector into
their genome were selected by G418 and analyzed for homologous
recombination by Southern blot analysis. Chimeric mice obtained after
blastocyst injection were mated to C57BL/6 mice for transmission of the
Insm1ΔSNAG allele. Routine genotyping was performed by PCR using the
following primers: Insm1ΔSNAG-fw CCCAACCAGTGCGTCGCCCTT
and Insm1ΔSNAG-rv AGCAGCGCCCGGTCACTGTCC.
In situ hybridization, X-Gal staining, BrdU labeling and
immunohistochemistry
For in situ hybridization, tissue was embedded into OCT compound directly
after dissection. Digoxygenin-labeled riboprobes, which were used for
hybridization, were generated by in vitro transcription. β-Galactosidase
activity was assessed by X-Gal staining as described previously (Lobe et al.,
1999). For immunohistochemistry, tissue was fixed with 4%
paraformaldehyde in 0.1 M sodium phosphate buffer (pH 7.4) and
cryoprotected in 25% sucrose in PBS prior to embedding, and cryosections
were cut at 14 μm thickness. The following primary antibodies were used:
rabbit/guinea pig anti-Insm1 (1:10,000; antibodies were raised against an
antigen produced in Escherichia coli and the plasmid used for production of
the antigen was kindly provided by G. Gradwohl, IGBMC Illkirch, France),
rabbit anti-ACTH (1:2000; AFP15610278912, NHPP, Torrance, USA),
chicken anti-β-galactosidase (1:5000; Ab9361, Abcam), rat anti-BrdU
antibodies (1:200; AbD Serotec), rat-anti ER/TR7 (1:500; Ab51829,
Abcam), rabbit anti-FSH (1:2000; AFP7798-1289, NHPP), rabbit anti-GH
(1:1000; Ab940, Merck-Millipore), rat anti-Ki67 (1:500; M724901-8, Dako
Cytomation), rabbit anti-LH (1:2000; AFPC697071P, NHPP), rabbit anti-
MSH (1:1000; Peninsula Laboratories LLC), goat anti-NeuroD1 (1:500; sc-
1084, Santa Cruz), rat anti-PECAM (1:300; 553930, BD Pharmingen),
rabbit anti-Prl (1:2000; AFP131078rb, NHPP), rabbit anti-S100 (1:1000;
4955
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Fig. 7. The SNAG domain is required for
Insm1 function. (A) Expression of Insm1
and Insm1ΔSNAG protein in the pituitary of
wild-type, Insm1+/ΔSNAG, Insm1lacZ/ΔSNAG,
Insm1+/lacZ and Insm1lacZ/lacZ mice was
assessed by western blotting using
antibodies against Insm1 and FLAG. Note
that the allele encoding Insm1ΔSNAG
contains a FLAG-tag (supplementary
material Fig. S4). (B) qPCR of lacZ
transcripts expressed in the pituitary of
Insm1+/lacZ and Insm1lacZ/ΔSNAG mice. 
(C-P) Analysis of hormone expression in the
pituitary of control and Insm1lacZ/ΔSNAG mice
at E17.5 using antibodies directed against
GH (C,D), TSH (E,F), FSH (G,H), LH (I,J),
Prl (K,L), MSH (M,N) and ACTH (O,P). Note
that all hormones are produced at much
reduced levels in Insm1ΔSNAG mutant mice.
(Q-T) Analysis of myosin light polypeptide 1
(Myl1; Q,R) and alpha cardiac muscle 1
actin (Actc1; S,T) expression by in situ
hybridization in the pituitary of control and
Insm1ΔSNAG mutant mice. (U-W) qPCR
analysis of proprotein convertases and
granins (U), various muscle-specific genes
(V) and components of the Notch signaling
pathway (W). Compared are pituitaries of
control (Insm1+/ΔSNAG and Insm1+/lacZ),
Insm1lacZ/lacZ and Insm1lacZ/ΔSNAG mice at
E17.5. *P<0.05; **P<0.01; ***P<0.001; n.s.,









Z0311, Dako), goat anti-Sox2 (1:500; GT15098, Immune Systems), rabbit
anti-Sox9 (1:2500; Ab5535, Merck-Millipore) and rabbit anti-TSH (1:1000;
Ab976, Merck-Millipore). Secondary antibodies conjugated to Cy2, Cy3 or
Cy5 were used at a dilution of 1:500 (Jackson ImmunoResearch). All
quantifications from histological sections were performed on at least three
sections of three or more animals/genotype. Unpaired Student’s two-tailed
t-tests were performed using Graphpad Prism 5 to determine significance.
Average and s.e.m. are displayed. For visualization of Myl1 and
Insm1ΔSNAG co-expression, in situ hybridization was combined with
immunohistochemistry. TUNEL was performed by the use of a kit (57110,
Merck-Millipore) according to the manufacturer’s instructions. DAPI was
used as a nuclear counterstain. Fluorescence was imaged on a Zeiss LSM
700 confocal microscope and images were processed using Adobe
Photoshop software.
Morphometric analysis
For the estimation of the volume and area of the pituitary gland, 14-μm-
thick sagittal sections were collected and Nissl stained. A total of 75
sections of the pituitary gland were obtained per animal (three
animals/genotype). The area of every third section was measured using
imaging analysis software (ImageJ; NIH, version 1.34n). Estimation of the
total volume of the pituitary gland was obtained by application of
Cavalieri’s method (West, 2012).
qRT-PCR and microarrays
E17.5 pituitary glands were dissected and total RNA was isolated using
Trizol reagent (Invitrogen). qRT-PCR analysis after first-strand cDNA
synthesis was performed using a CFX96 RT-PCR system (Bio-Rad),
ABsolute QPCR SYBR Green Mix (Thermo Fisher Scientific) and the
primers are listed in supplementary material Table S1. Total RNA from
pituitary glands was labeled and hybridized to MouseRef-8 v2.0 Expression
BeadChips (Illumina, San Diego, CA, USA) according to the manufacturer's
protocol. 
Microarray data analysis
All microarray datasets were analyzed using R Bioconductor package
(Gentleman et al., 2004). To compare samples, we applied log2
transformation and normalized using the ‘quantile’ method, and adjusted P-
values were obtained using the Benjamini-Hochberg FDR method (cutoff
P<0.05 for all cell types). Expression data of control and Insm1 mutant
pituitary glands have been deposited in NCBI’s Gene Expression Omnibus
(Edgar et al., 2002) and are accessible through accession number
GSE46139.
Cell culture, biochemical experiments, mass spectrometry and
data analysis
AtT-20 and GH3 cells were grown in high-glucose DMEM
(Gibco/Invitrogen) containing 10% fetal calf serum (FCS; Sigma-Aldrich).
For SILAC experiments, AtT-20 cells were grown in SILAC DMEM (PAA
Laboratories, Velizy-Villacoublay, France), 10% dialyzed FCS (SAFC),
4 mM glutamine and amino acids labeled either with ‘light’
[12C;14N]arginine/lysine (Sigma-Aldrich) or ‘heavy’ [13C;15N]arginine/lysine
(Sigma-Aldrich) isotopes for four passages.
For immunoprecipitation, cells were washed with PBS, harvested in lysis
buffer containing 50 mM Tris pH 7.4, 140 mM NaCl, 1% Triton X-100,
complete protease inhibitors (Roche) and phosphatase inhibitor cocktails 2
and 3 (Sigma-Aldrich). After pre-clearing, supernatants were incubated with
antibodies conjugated and covalently coupled to Dynabeads ProteinA/G for
3 hours at 4°C. Precipitates of the corresponding ‘heavy’ and ‘light’ pull-
downs were combined and washed three times with lysis buffer. The last
wash was performed with 5 mM Tris pH 7.4, 140 mM NaCl. Bound proteins
were eluted with 3×100 μl 100 mM glycine pH 2.5 and subsequently
precipitated by adding 1 μl GlycoBlue (Ambion/Life Technologies), 80 μl
2.5 M sodium acetate pH 5.0 and 1500 μl ethanol. Sedimentation was
carried out at 20,000 g for 30 minutes. Protein pellets were dissolved in 
6 M urea/2 M thiourea/10 mM HEPES (pH 8.0), reduced with 1 mM
dithiothreitol, alkylated with 5.5 mM iodoacetamid and subsequently
digested by lysyl-endopeptidase (Lys-C, Wako Chemicals) and sequencing
grade modified trypsin (Promega) in 50 mM ammonium bicarbonate
following standard procedures (Shevchenko et al., 2007). Peptides were
desalted by stop and go extraction (STAGE) tips containing C18 Empore
disks (3M) (Rappsilber et al., 2003). Peptide mixtures were analyzed by C18
reversed phase nanoflow HPLC on an Eksigent nanoLC-1D Plus system
(Eksigent Technologies) coupled to an LTQ-Orbitrap XL mass spectrometer
(Thermo Fisher Scientific). Mass spectrometers were operated in the data-
dependent mode with a TOP5 method (Olsen et al., 2005). Raw data files
were processed using the MaxQuant software platform with standard
settings (Cox and Mann, 2008; Cox et al., 2009). Peak lists were searched
against an in-house curated mouse International Protein Index (IPI) human
protein database using MASCOT (Matrix Science, Boston, USA) and a
database containing common contaminants. Proteins with one unique
peptide were considered identified, and peptide and protein false discovery
rates were restricted to 0.01.
For western blot analysis, immunoprecipitated proteins were eluted from
beads by boiling in 1 × Laemmli buffer for 5 minutes and then subjected to
SDS-PAGE. Proteins were transferred to PVDF membranes. The following
antibodies were used for western blot analysis: rabbit anti-Kdm1a (1:1000,
#2139, Cell Signaling Technology), goat anti-CoREST (1:200, sc-23448,
Santa Cruz), rabbit anti-Hdac1 (1:1000, #2062, Cell Signaling Technology),
rabbit anti-Hdac2 (1:2000, ab32117, Merck-Millipore), rabbit/guinea pig
anti-Insm1 (1:6000), mouse anti-tubulin (1:10,000, T9026, Sigma-Aldrich),
mouse anti-Flag (1:1000, F1804, Sigma-Aldrich). Secondary antibodies
coupled to horseradish peroxidase (Dianova, Hamburg, Germany) were
used, and blots were developed on a Chemi-smart 3000 (Vilber,
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Fig. 8. Mutant endocrine cells in Insm1lacZ/ΔSNAG mice maintain Sox2/9
expression and ectopically express the muscle-specific gene Myl1. 
(A-F) Immunohistological analysis of co-expressed Sox2/Sox9 and wild-
type/truncated Insm1 protein in control (Insm1+/ΔSNAG) and mutant
Insm1lacZ/ΔSNAG mice (A,B,D,E); quantification of co-expressing cells in the
anterior lobe of the pituitary (C,F). (G,H) Analysis of co-expression of Myl1
and wild-type/truncated Insm1 in control (Insm1+/ΔSNAG) and mutant
Insm1lacZ/ΔSNAG mice; arrowheads indicate that a subpopulation of Insm1+
cells co-expresses Myl1 in the mutant pituitary. (I) Summary of Insm1
functions in gene expression in endocrine cells of the pituitary. Insm1
suppresses the expression of progenitor markers (Sox2/9), various
components of the Notch pathway (Notch2, Dll1) and muscle-specific genes
(Myl1, Actc1) in developing endocrine cells of the pituitary, and drives
differentiation and hormone gene expression. **P<0.01. Scale bars: 25 μm








Eberhardzell, Germany). Wild-type and modified Insm1 cDNAs [Insm1FLAG
(Insm1 containing 3xFLAG-tag, Sigma-Aldrich), Insm1ΔSNAGFLAG
(Insm1ΔSNAG containing 3xFLAG-tag, Sigma-Aldrich)] were expressed
in AtT-20 cells using a MMULV-based system developed by the Nolan lab
(http://www.stanford.edu/group/nolan/retroviral_systems/phx.html).
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Fig. S1. Insm1 expression in the adult pituitary gland and reduced transcription of genes encoding pituitary hormones. Whole 
mount X-Gal staining of a P60 Insm1+/lacZ pituitary gland demonstrates transcriptional activity of the Insm1 locus in the adult (A). 
Transcript levels of hormone coding genes were assessed by in situ hybridization in control and mutant (Insm1lacZ/lacZ) mice at E17.5 
(B-M). GH (B,C), TSHb (D,E), FSHb (F,G) and LHb (H,I) transcripts were abundant in control pituitaries and absent in pituitaries of 
Insm1lacZ/lacZ mice, and Cga (J,K) and POMC (L,M) transcripts were present at reduced levels in mutants. Scale bar: 100 µm.
Fig. S2. The Insm1 mutation does not promote proliferation or cell death. Proliferation was assessed at E13.5 and E15.5 by BrdU 
incorporation (A-C) in control (Insm1+/lacZ) and mutant (Insm1lacZ/lacZ) mice. Nuclei were counterstained with DAPI, and the percentage 
of BrdU+ cells was determined (C). Apoptosis was assessed by Terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) assay at E13.5 (D,E) and E15.5 (F,G). In control and mutant mice at E13.5 or E15.5, a few apoptotic cells (arrows) were 
observed in parenchymal and other tissues adjacent to the pituitary gland, but not within the gland (D-G). Scale bars: 100 µm.
Fig. S3. Pituitary endocrine cells are specified correctly in Insm1 mutant mice. The expression of transcription factors expressed 
during specification of pituitary endocrine cells was assessed by in situ hybridization. The transcripts of Hesx1 (A,B), Pitx1 (C,D), 
Pitx2 (E,F), Lhx3 (G,H), and Prop1 (I-P) were detected at comparable levels in control (Insm1+/lacZ) and mutant (Insm1lacZ/lacZ) mice at 
E12 or E13.5. At E14.5 and E15.5, expression of Prop1 was mildly enhanced in the anterior lobe. Scale bar: 100 µm.
Fig. S4. Generation of Insm1ΔSNAG mutant mice. Schematic representation of the targeting vector, the wild-type Insm1 locus, and the 
mutated Insm1ΔSNAG allele (A). Coding (red) and non-coding (orange) sequences, the SNAG domain (green), the N-terminal 3xFLAG-
tag (grey), DTA, the self-excision neomycin cassette, loxP (arrowhead), Southern blot probes (red bars) and BglII, EcoRV and PacI 
restriction sites are depicted. Black lines indicate the predicted fragment sizes obtained after digestion of genomic DNA. G418 
resistant clones were analyzed by Southern blotting (B). Hybridization with a probe located 5′ of the targeting vector detected 15.1 kb 
and 9.8 kb DNA fragments corresponding to Insm1 wildtype and Insm1ΔSNAG alleles, respectively; the DNA from ES cells was digested 
with BglII/EcoRV. Hybridization with a probe located 3′ of the targeting vector detected 26 kb and 12.2 kb fragments of Insm1 
wildtype and Insm1ΔSNAG alleles; the DNA was digested by PacI/EcoRV. A probe containing sequences present in the targeting vector 
was used to ensure the absence of random integration events. (C) Insm1 wildtype and Insm1ΔSNAG alleles are distinguishable by PCR. 
PCR amplification of Insm1 wildtype and Insm1ΔSNAG alleles produce a 127 bp and 106 bp fragment, respectively.
Fig. S5. Comparison of gene expression changes in three different endocrine cell types of Insm1 mutant mice. Cross comparison 
of expression changes (log2 values are given) in three different (adrenergic, pancreatic and pituitary) endocrine organs of Insm1 
mutant versus control mice. Green: linear regression line and Pearson’s correlation coefficients. Each scatter plot represents genes 
that are deregulated in both organs (FC more than 1.7). (A) Comparison of deregulated genes in the adrenal gland and pancreas (116 
genes); (B) Comparison of deregulated genes in the pituitary and pancreas (81 genes); (C) Comparison of deregulated genes in the 
pituitary and adrenal gland (482 genes).
Fig. S6. Mutation of Insm1 results in an increased number of cells that retain progenitor characteristics. Immunohistochemical 
analysis of endocrine progenitor cells using antibodies directed against Sox2 (A,B), Sox9 (D,E) and Insm1 (G,H) in the pituitary 
of Insm1 control (Insm1+/ΔSNAG) and mutant (Insm1lacZ/ΔSNAG) mice at E17.5. Quantification of numbers of Sox2+ (C), Sox9+ (F) and 
Insm1+ cells (I) in the anterior lobe of the pituitary; whereas the numbers of Sox2+ and Sox9+ cells were increased, the number of 
Insm1+ cells was not significantly changed. Scale bars: 25 µm. **P<0.01
 1 
Table S1. Primers used for qRT-PCR 
Name Primer Sequence 5' to 3' 
Myl1-fw  CACATCATGTCTGTCTAAACGG 
Myl1-rv  CTGGTGTTGACAGTTAGCCAT 
Actc1-fw  AGGCCCATCCATTGTCCA 
Actc1-rv  CAAGAAGCACAATACGGTCA 
Msc-fw  GCTTTGTGGAACTTCCGCTT 
Msc-rv  AGGGCAAACCACACTTGTCT 
Chga-fw ACACTTCTGCAGGGCAGC 
Chga-rv AGTTATTGCAGTTGTGCCCC 
Chgb-fw  ATTCACCCACAGGCAGAAAG 
Chgb-rv  ACAAGTCACGCTAGTCACATGG 
Pcsk1-fw  CCATGCTGCGACTCCT 
Pcsk1-rv  TGATTGTTTTGAAAGTGCATT 
Pcsk2-fw  ACCTTTGGCATCAGTATTAACACC 
Pcsk2-rv  CATCAGACTCAGGGGCATCA 
Scg3-fw  TGTCTCGGCATGCTAGACAC 
Scg3-rv  GACGTGGGTTTATTTCCGTG 
Notch2-fw GCTATAAGTGCCTCTGCGAT 
Notch2-rv AGGCACACTCATCTATATTCACC 
Dll1-fw  GATACACACAGCAAACGTGACACC 
Dll1-rv TTCCATCTTACACCTCAGTCGCTA 
Hes1-fw  CAGACATTCTGGAAATGACTGTGAA 
Hes1-rv  CGCGGTATTTCCCCAACAC 
Hes5-fw  GCTCCGCTCGCTAATCGCCTCCAG 
Hes5-rv  GTCCCGACGCATCTTCTCCACCAC 
Hey1-fw  GCCGACGAGACCGAATCAATAACA 
Hey1-rv  TCCCGAAACCCCAAACTCCGATAG 
 
 
